SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, has unveiled new data on a novel approach to chronic pain management and joint tissue preservation. The data highlight SN101, a first-in-class induced pluripotent stem cell (iPSC)-derived therapy.

The announcement was made at the International Society for Stem Cell Research (ISSCR) Symposium Accelerating PSC-Derived Cell Therapies: Starting with the End in Mind.